"10.1371_journal.pone.0138032","plos one","2015-09-23T00:00:00Z","Lei Xu; Xueying Mao; Ahmet Imrali; Ferrial Syed; Katherine Mutsvangwa; Daniel Berney; Paul Cathcart; John Hines; Jonathan Shamash; Yong-Jie Lu","Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China; Department of Medical Oncology, Barts Health NHS, London, United Kingdom; Centre for Experimental Medicine, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Department of Urology, University College Hospital NHS, London, United Kingdom; Department of Urology, Barts Health NHS, London, United Kingdom","Conceived and designed the experiments: LX XM JS YJL. Performed the experiments: LX XM AI. Analyzed the data: LX XM YJL. Contributed reagents/materials/analysis tools: LX FS KM DB PC JH JS. Wrote the paper: LX XM YJL.","The authors have the following interests. This study was partially supported by ANGLE PLC, who owns the Parsortix system. Most of the work using the IsoFlux system was done on a demonstration machine provided by Fluxion Biosciences. The study was planned and conducted and the data are presented independently of both companies. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","09","Lei Xu","LX",10,TRUE,4,3,3,3,TRUE,TRUE,FALSE,0,NA,FALSE
